2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealmentPercutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation
Noseworthy PA, Van Houten HK, Krumholz HM, Kent DM, Abraham NS, Graff‐Radford J, Alkhouli M, Henk HJ, Shah ND, Gersh BJ, Friedman PA, Holmes DR, Yao X. Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation. Journal Of The American Heart Association 2022, 11: e027001. PMID: 36172961, PMCID: PMC9673739, DOI: 10.1161/jaha.121.027001.Peer-Reviewed Original ResearchConceptsComposite end pointAtrial appendage occlusionOral anticoagulantsAtrial fibrillationLower riskMajor bleedingSystemic embolismIntracranial bleedingAppendage occlusionNon-Vitamin K Antagonist Oral AnticoagulantsIschemic stroke/systemic embolismK Antagonist Oral AnticoagulantsPrimary composite end pointPropensity score overlap weightingStroke/systemic embolismEnd pointHigh bleeding riskSignificant differencesAntithrombotic regimensBleeding riskCause mortalityBaseline characteristicsComposite outcomeIschemic strokeSecondary outcomes
2021
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 JACC State-of-the-Art Review
Talasaz AH, Sadeghipour P, Kakavand H, Aghakouchakzadeh M, Kordzadeh-Kermani E, Van Tassell BW, Gheymati A, Ariannejad H, Hosseini SH, Jamalkhani S, Sholzberg M, Monreal M, Jimenez D, Piazza G, Parikh SA, Kirtane AJ, Eikelboom JW, Connors JM, Hunt BJ, Konstantinides SV, Cushman M, Weitz JI, Stone GW, Krumholz HM, Lip GYH, Goldhaber SZ, Bikdeli B. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19 JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2021, 77: 1903-1921. PMID: 33741176, PMCID: PMC7963001, DOI: 10.1016/j.jacc.2021.02.035.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19COVID-19 Drug TreatmentFibrinolytic AgentsHumansRandomized Controlled Trials as TopicThromboembolismConceptsCOVID-19Recent randomized trialsCommon pathophysiological featuresDuration of therapyClinical trial enterpriseMacrovascular thrombosisThromboprophylactic regimensAntithrombotic therapyAntithrombotic strategiesEndothelial injuryFuture RCTsMedical wardsIllness severityRandomized trialsPathophysiological featuresJACC StateAntithrombotic agentsCoronavirus diseasePatientsRCTsTherapyTrialsRegimensThrombosisOutpatients
2020
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research
Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Group T. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis And Haemostasis 2020, 120: 1004-1024. PMID: 32473596, PMCID: PMC7516364, DOI: 10.1055/s-0040-1713152.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Subgroup of patientsCOVID-19 patientsFuture prospective studiesManagement of thrombosisSyndrome coronavirus 2Coronavirus disease 2019Mechanism of actionViral illnessThrombotic eventsRandomized trialsProspective studyAntithrombotic effectCoronavirus 2Antithrombotic agentsAntithrombotic drugsAntiviral effectDisease 2019Thrombotic diseaseAntithrombotic propertiesDosing approachWorldwide pandemicCOVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH, Global COVID-19 Thrombosis Collaborative Group E. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2020, 75: 2950-2973. PMID: 32311448, PMCID: PMC7164881, DOI: 10.1016/j.jacc.2020.04.031.Peer-Reviewed Original ResearchConceptsAntithrombotic therapyThrombotic diseaseCOVID-19Outcomes of patientsViral respiratory illnessEndothelial dysfunctionArterial thrombosisThromboembolic diseaseExcessive inflammationRespiratory illnessLaboratory monitoringJACC StateArterial circulationPlatelet activationPatientsCoronavirus diseaseDiseaseTherapyCOVID-19 pandemicPreventionCurrent understandingThromboticThrombosisInflammationDysfunction
2016
Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionFibrinolytic therapyMyocardial infarctionPercutaneous coronary intervention capabilitySequential cross-sectional studiesChina PEACE-Retrospective AMI StudyPrimary reperfusion strategyPercutaneous coronary interventionLittle clinical evidenceCross-sectional studyQuality of careTwo-stage random samplingCoronary interventionHospital delayNeedle timeReperfusion strategySymptom onsetTherapy useClinical evidenceEmergency departmentMedian admissionIdeal patientPatientsWeighted proportion
2015
Sex Differences in Reperfusion in Young Patients With ST-Segment–Elevation Myocardial Infarction
D'Onofrio G, Safdar B, Lichtman JH, Strait KM, Dreyer RP, Geda M, Spertus JA, Krumholz HM. Sex Differences in Reperfusion in Young Patients With ST-Segment–Elevation Myocardial Infarction. Circulation 2015, 131: 1324-1332. PMID: 25792558, PMCID: PMC4652789, DOI: 10.1161/circulationaha.114.012293.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionMyocardial infarctionReperfusion therapyAcute ST-segment elevation myocardial infarctionProspective observational cohort studyYoung AMI Patients (VIRGO) studyTime guidelinesYoung womenObservational cohort studyProportion of patientsElevation myocardial infarctionPercutaneous coronary interventionYears of ageSex differencesPatients 18Reperfusion strategyCohort studyCoronary interventionFibrinolytic therapyNeedle timeYounger patientsReperfusion delayRatio of womenReperfusion guidelinesSex disparities
2014
ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data
Li J, Li X, Wang Q, Hu S, Wang Y, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. The Lancet 2014, 385: 441-451. PMID: 24969506, PMCID: PMC4415374, DOI: 10.1016/s0140-6736(14)60921-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAspirinChinaClopidogrelFemaleFibrinolytic AgentsHealthcare DisparitiesHospital MortalityHospitals, RuralHospitals, UrbanHumansMaleMiddle AgedMyocardial InfarctionMyocardial ReperfusionPatient AdmissionPercutaneous Coronary InterventionQuality of Health CareRetrospective StudiesTiclopidineTreatment OutcomeConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionHospital mortalityHospital admissionMyocardial infarctionRetrospective analysisPrimary percutaneous coronary interventionAcute myocardial infarction admissionsProportion of patientsUse of aspirinPercutaneous coronary interventionMyocardial infarction admissionsTwo-stage random sampling designQuality of careAnalysis of treatmentBaseline characteristicsCardiac eventsHospital outcomesHospital stayCoronary interventionFamily Planning CommissionClinical profileHospital recordsMedian lengthSTEMI admissions
2008
An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials
Wijeysundera HC, You JJ, Nallamothu BK, Krumholz HM, Cantor WJ, Ko DT. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: A meta-analysis of contemporary randomized controlled trials. American Heart Journal 2008, 156: 564-572.e2. PMID: 18760142, DOI: 10.1016/j.ahj.2008.04.024.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryCardiac CatheterizationElectrocardiographyFemaleFibrinolytic AgentsHemorrhageHumansInjections, IntravenousInpatientsMaleMiddle AgedMyocardial InfarctionMyocardial IschemiaMyocardial ReperfusionRandomized Controlled Trials as TopicRecurrenceStentsStrokeThrombolytic TherapyConceptsST-segment elevation myocardial infarctionEarly invasive strategyPercutaneous coronary interventionElevation myocardial infarctionFibrinolytic therapyInvasive strategyMajor bleedingSTEMI patientsMyocardial infarctionHospital major bleedingIntravenous fibrinolytic therapyLarge randomized trialsRisk of strokeSignificant reductionCause mortalityEligible trialsCoronary interventionRandomized trialsContemporary trialsStent useInclusion criteriaPatientsReinfarctionTherapyTrials
2007
Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Herrin J, Wang Y, Curtis JP, Bradley EH, Magid DJ, Rathore SS, Nallamothu BK, Peterson ED, Blaney ME, Frederick P, Krumholz HM. Impact of Delay in Door-to-Needle Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. The American Journal Of Cardiology 2007, 100: 1227-1232. PMID: 17920362, PMCID: PMC2715362, DOI: 10.1016/j.amjcard.2007.05.043.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overArrhythmias, CardiacCaliforniaCohort StudiesEmergency Service, HospitalEmergency TreatmentFemaleFibrinolytic AgentsHospital MortalityHumansMaleMedical RecordsMyocardial InfarctionOutcome Assessment, Health CareRegistriesRetrospective StudiesThrombolytic TherapyTime and Motion StudiesTime FactorsConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionNeedle timeFibrinolytic therapyMyocardial infarctionHospital mortalitySymptom onsetOdds ratioReperfusion strategyAdjunctive medicationsHospital arrivalShorter doorTimely administrationNational registryRepresentative cohortPatientsMortalityInfarctionTherapyIndependent effectsCohortMinutesSmaller centersOnsetImpact of delayAcute Coronary Care in the Elderly, Part II
Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, Van de Werf F, White HD, Weaver WD, Naylor MD, Gore JM, Krumholz HM, Ohman EM. Acute Coronary Care in the Elderly, Part II. Circulation 2007, 115: 2570-2589. PMID: 17502591, DOI: 10.1161/circulationaha.107.182616.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAge FactorsAgedAged, 80 and overAngina, UnstableAngioplasty, Balloon, CoronaryCardiovascular AgentsClinical Trials as TopicCombined Modality TherapyDisease ManagementDisease SusceptibilityEvidence-Based MedicineFemaleFibrinolytic AgentsGeriatricsHumansMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial RevascularizationPatient RightsPractice Guidelines as TopicPrejudiceQuality of LifeRegistriesRisk FactorsStentsThrombolytic TherapyTreatment OutcomeConceptsST-segment elevation myocardial infarctionElderly patientsMyocardial infarctionInvasive treatmentAmerican Heart Association scientific statementOlder adultsComplex health statusGuideline-recommended careTreatment-associated risksAcute coronary syndromeAcute coronary careTreatment-related benefitsAge 85 yearsPatient-centered mannerQuality of lifeLimited trial dataCoronary syndromeReperfusion strategyAbsolute contraindicationAdjunctive therapyCardiovascular medicationsOlder patientsCoronary careGeriatric conditionsElderly subgroupRescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction A Meta-Analysis of Randomized Trials
Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, Foody JM, Krumholz HM, Phillips CO, Kashani A, You JJ, Tu JV, Ko DT. Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction A Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2007, 49: 422-430. PMID: 17258087, DOI: 10.1016/j.jacc.2006.09.033.Peer-Reviewed Original ResearchConceptsRescue percutaneous coronary interventionPercutaneous coronary interventionST-segment myocardial infarctionFibrinolytic therapyCause mortalityMinor bleedingRandomized trialsRisk of strokeSignificant clinical improvementImproved clinical outcomesSignificant risk reductionFixed-effects modelRescue angioplastySTEMI patientsClinical improvementConservative managementConservative treatmentCoronary interventionHospital dischargeHeart failureClinical outcomesMyocardial infarctionBest therapyCommon treatmentPatients
2006
Delay in the Diagnosis of Acute Myocardial Infarction: Effect on Quality of Care and Its Assessment
Graff LG, Wang Y, Borkowski B, Tuozzo K, Foody JM, Krumholz HM, Radford MJ. Delay in the Diagnosis of Acute Myocardial Infarction: Effect on Quality of Care and Its Assessment. Academic Emergency Medicine 2006, 13: 931-938. PMID: 16894002, DOI: 10.1197/j.aem.2006.04.016.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAge DistributionAgedAged, 80 and overAngina, UnstableAspirinCohort StudiesConnecticutEvidence-Based MedicineFemaleFibrinolytic AgentsHumansMaleMyocardial InfarctionPatient AdmissionQuality Assurance, Health CareQuality of Health CareRetrospective StudiesTime FactorsConceptsAcute myocardial infarctionAdmission diagnosisBeta blockersQuality of careMyocardial infarctionDiagnosis of AMICharacteristics of patientsPercutaneous coronary interventionPrincipal discharge diagnosisEvidence-based therapiesRate of administrationCoronary interventionCardiac catheterizationDischarge diagnosisPrincipal diagnosisFrequency of delaysDischarge statusPatient careAdmissionAMI diagnosisPatientsDiagnosisMedicare casesCareInfarctionDoor-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI)
Bradley EH, Herrin J, Wang Y, McNamara RL, Radford MJ, Magid DJ, Canto JG, Blaney M, Krumholz HM. Door-to-drug and door-to-balloon times: Where can we improve? Time to reperfusion therapy in patients with ST-segment elevation myocardial infarction (STEMI). American Heart Journal 2006, 151: 1281-1287. PMID: 16781237, DOI: 10.1016/j.ahj.2005.07.015.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionPatients' clinical characteristicsBalloon timeClinical characteristicsDrug timeMyocardial infarctionProportion of patientsElevation myocardial infarctionHospital-level variationTreatment of patientsCross-sectional analysisHigh performing hospitalsReperfusion therapyNational registryHospitalPatientsRegression modelingECGDrugsInfarctionHierarchical regression modelingHospital performanceImportant quality indicatorMinutesGeometric mean
2003
Regional variation in the treatment and outcomes of myocardial infarction: investigating New England’s advantage
Krumholz HM, Chen J, Rathore SS, Wang Y, Radford MJ. Regional variation in the treatment and outcomes of myocardial infarction: investigating New England’s advantage. American Heart Journal 2003, 146: 242-249. PMID: 12891191, DOI: 10.1016/s0002-8703(03)00237-0.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAngioplasty, Balloon, CoronaryAspirinCoronary Artery BypassFemaleFibrinolytic AgentsHospitalizationHumansLogistic ModelsMaleMyocardial InfarctionNew EnglandOutcome Assessment, Health CarePractice Patterns, Physicians'Quality of Health CareThrombolytic TherapyUnited StatesConceptsPractice patternsMortality rateReperfusion therapyBetter short-term outcomesMedical therapy useShort-term outcomesQuality of careHierarchical logistic regression modelsMyocardial infarction treatmentLogistic regression modelsTherapy useMyocardial infarctionHospital characteristicsPhysician characteristicsProvider characteristicsBetter outcomesInfarction treatmentPatientsMI treatmentRegional variationLow useRegional differencesAspirinHospitalTherapy
2002
Nonsteroidal antiinflammatory drugs after acute myocardial infarction
Ko D, Wang Y, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. American Heart Journal 2002, 143: 475-481. PMID: 11868054, DOI: 10.1067/mhj.2002.121270.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionNonsteroidal antiinflammatory drugsNSAID therapyMyocardial infarctionAddition of aspirinMortality rateAspirin therapyElderly patientsAntiinflammatory drugsMedicare beneficiariesUse of NSAIDsRetrospective medical record reviewAdditional survival benefitMedical record reviewCooperative Cardiovascular ProjectElderly Medicare beneficiariesHospital dischargeOlder patientsSurvival benefitRecord reviewClinical informationInfarctionAspirinPatientsMedications
2000
Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction
Brass L, Lichtman J, Wang Y, Gurwitz J, Radford M, Krumholz H. Intracranial Hemorrhage Associated With Thrombolytic Therapy for Elderly Patients With Acute Myocardial Infarction. Stroke 2000, 31: 1802-1811. PMID: 10926938, DOI: 10.1161/01.str.31.8.1802.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionThrombolytic therapyIntracranial hemorrhageMyocardial infarctionElderly patientsIntracranial Hemorrhage AssociatedRetrospective cohort studyRisk stratification scaleMain outcome measuresAcute care hospitalsTissue plasminogen activatorExcessive anticoagulationPrior strokeCohort studyOlder patientsBlood pressureHemorrhage AssociatedIndependent predictorsMedical chartsSerious complicationsMedian weightAlternate therapyBlack racePrincipal diagnosisMedicare patients
1999
Thrombolytic therapy: Economic considerations
Krumholz H. Thrombolytic therapy: Economic considerations. American Heart Journal 1999, 137: s87-s89. PMID: 10220605, DOI: 10.1016/s0002-8703(99)70437-0.Peer-Reviewed Original ResearchEconomics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial
Weintraub W, Culler S, Kosinski A, Becker E, Mahoney E, Burnette J, Spertus J, Feeny D, Cohen D, Krumholz H, Ellis S, Demopoulos L, Robertson D, Boccuzzi S, Barr E, Cannon C. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina with Aggrastat® [tirofiban] and Determine Cost of Therapy with Invasive or Conservative Strategy)–TIMI 18 trial. The American Journal Of Cardiology 1999, 83: 317-322. PMID: 10072215, DOI: 10.1016/s0002-9149(98)00860-1.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsHealth Utilities IndexLife yearsHealth-related qualityCost-effectiveness methodsNon-Q-wave myocardial infarctionUtility indexCost-effectiveness analysisDetermine CostImpact of invasiveEconomic formsUB92 formulationHealth care costsUnstable anginaRelative value scaleMedicare conversion factorMyocardial infarctionMedicare fee scheduleDepartmental costsEconomicsExpensive formFee scheduleTACTICS-TIMI 18Care costsOutcomes of patients
1998
GENDER DIFFERENCES IN MORTALITY AFTER MYOCARDIAL INFARCTION Why Women Fare Worse Than Men
Nohria A, Vaccarino V, Krumholz H. GENDER DIFFERENCES IN MORTALITY AFTER MYOCARDIAL INFARCTION Why Women Fare Worse Than Men. Cardiology Clinics 1998, 16: 45-57. PMID: 9507780, DOI: 10.1016/s0733-8651(05)70383-0.Peer-Reviewed Original Research